Literature DB >> 16617702

Western blot immunoassay as a confirmatory test for the presence of anti-Mycoplasma hyopneumoniae antibodies in swine serum.

Mehrdad Ameri1, En-Min Zhou, Walter H Hsu.   

Abstract

A Western blot immunoassay (WBI) was developed as a confirmatory test for 2 commercial Mycoplasma hyopneumoniae (Mhyo) ELISAs. The WBI detected at least 5 antigen bands (150, 130, 74, 70, and 30 kDa) from Mhyo whole membrane proteins that were not present in the antigens prepared from M. hyorhinis and M. hyosynoviae. Among discrepant sera from vaccinated pigs (n = 17) and field samples (n = 91) assayed by WBI: 1) 2 of the ELISA-positive samples reacted with all 5 antigens bands; 2) all blocking ELISA-positive samples (n = 53) bound 150-, 130-, 74-, and 70-kD antigen bands; and 3) all indirect ELISA-positive samples (n = 55) bound 150-, 130-, and 30-kD antigens. We conclude that the WBI targeting the top 4 antigen bands is a useful confirmatory test for samples initially screened using the commercial Mhyo ELISAs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16617702     DOI: 10.1177/104063870601800210

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  3 in total

1.  Mycoplasma agassizii strain variation and distinct host antibody responses explain differences between enzyme-linked immunosorbent assays and Western blot assays.

Authors:  Lori D Wendland; Paul A Klein; Elliott R Jacobson; Mary B Brown
Journal:  Clin Vaccine Immunol       Date:  2010-09-01

2.  Monoclonal antibodies directed against chicken β2-microglobulin developed with a synthesized peptide.

Authors:  Chuan Yu; Qiu Liu; Wei Gao; Kun Qian; Mei Mei; Hong-Xia Shao; Gen-Hua Wu; Wen-Jie Jin; Ai-Jian Qin
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2013-06

Review 3.  Current perspectives on the diagnosis and epidemiology of Mycoplasma hyopneumoniae infection.

Authors:  Marina Sibila; Maria Pieters; Thomas Molitor; Dominiek Maes; Freddy Haesebrouck; Joaquim Segalés
Journal:  Vet J       Date:  2008-04-08       Impact factor: 2.688

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.